- Home
- TDC vs RDY Comparison
TDC vs RDY Comparison
Compare TDC & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDC
- RDY
- Stock Information
- Founded
- TDC 1979
- RDY 1984
- Country
- TDC United States
- RDY India
- Employees
- TDC N/A
- RDY N/A
- Industry
- TDC Computer Software: Prepackaged Software
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- TDC Technology
- RDY Health Care
- Exchange
- TDC Nasdaq
- RDY Nasdaq
- Market Cap
- TDC 2.3B
- RDY 2.1B
- IPO Year
- TDC 2007
- RDY N/A
- Fundamental
- Price
- TDC $22.68
- RDY $13.53
- Analyst Decision
- TDC Hold
- RDY Buy
- Analyst Count
- TDC 9
- RDY 1
- Target Price
- TDC $30.00
- RDY $17.00
- AVG Volume (30 Days)
- TDC 1.0M
- RDY 2.2M
- Earning Date
- TDC 05-06-2025
- RDY 05-16-2025
- Dividend Yield
- TDC N/A
- RDY 0.73%
- EPS Growth
- TDC 241.18
- RDY 2.68
- EPS
- TDC 1.41
- RDY 0.75
- Revenue
- TDC $1,703,000,000.00
- RDY $3,637,607,642.00
- Revenue This Year
- TDC N/A
- RDY $17.74
- Revenue Next Year
- TDC $0.55
- RDY $9.32
- P/E Ratio
- TDC $16.14
- RDY $17.82
- Revenue Growth
- TDC N/A
- RDY 14.74
- 52 Week Low
- TDC $18.43
- RDY $12.26
- 52 Week High
- TDC $38.45
- RDY $16.89
- Technical
- Relative Strength Index (RSI)
- TDC 60.86
- RDY 52.27
- Support Level
- TDC $21.30
- RDY $13.17
- Resistance Level
- TDC $22.46
- RDY $14.06
- Average True Range (ATR)
- TDC 0.61
- RDY 0.20
- MACD
- TDC 0.29
- RDY -0.05
- Stochastic Oscillator
- TDC 96.87
- RDY 54.44
About TDC Teradata Corporation
Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.